The German Cancer Research Center (DKFZ) is one of Europe’s largest cancer research centers. “Research for a life without cancer" is the mission of our world-class scientists and all our team members.
The DKFZ is a place where the brightest minds pursue bold ideas and seek answers to pioneering scientific questions through collaboration, innovation, and exploration across many disciplines. We provide a dynamic environment which empowers excellence with state-of-the-art technologies, cutting edge infrastructure, and a global scientific network.
Contribute your knowledge, vision, and dedication to create a space where scientific discovery in cancer research is transformed into benefits for human health.
The Helmholtz Institute HI-TRON is a collaboration of the German Cancer Research Center with the Research Institute for Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz (TRON gGmbH), the University Medical Center Mainz and the Johannes Gutenberg University Mainz. The goal of the partnership is to develop effective immunotherapies and to identify novel biomarkers for assessing the effectiveness of treatment.
To strengthen the HI-TRON team in Mainz, we are seeking for the next possible date a skilled and motivated
Reference number: 2025-0293
The Division of Personalized Immunotherapy (headed by Prof. Dr. Özlem Türeci) at HI-TRON Mainz is looking for an individual with a strong background in oncoimmunology and a passion for developing innovative immunotherapies. The successful candidate will be instrumental in advancing fundamental knowledge and creating novel technologies to improve responsiveness to immune checkpoint inhibitors via cell-specific mRNA delivery.
Project Summary:
Exhausted CD8+ T cells in human tumors represent a highly heterogeneous population composed of multiple functional and developmental subsets. Recent studies identified a precursor/progenitor exhausted T cell subset characterized by TCF-1 expression, proliferative potential, and multilineage differentiation capacity. These cells serve as the critical reservoir that gives rise to intermediate and terminally exhausted subsets, which, although cytotoxic, display high inhibitory receptor expression and limited persistence.
Notably, clinical responses to anti–PD-1 immune checkpoint blockade correlate strongly with the presence and expansion of these precursor/progenitor exhausted CD8+ T cells. However, a substantial proportion of patients fail to respond despite tumor-infiltrating CD8+ T cells, suggesting that the composition of exhausted T cell subsets — not merely their presence — is a determinant of therapy success.
This project aims to expand precursor/progenitor exhausted CD8+ T cells through enforced expression of specific transcription factors using targeted mRNA delivery technologies, with the vision of enhancing responsiveness to immune checkpoint inhibitors.
Key Responsibilities:
Required Qualifications:
Preferred / Desirable Skills:
Please submit:
Contact:
Dr. Ibrahim Murathan Sektioglu
Phone: +49 (0)6131/179816
Duration: The position is initially limited to 2 years, with the possibility of prolongation.
Application Deadline: 12.12.2025
Applications by e-mail cannot be accepted.
Please also note that we cannot return applications submitted by post.
Then become part of the DKFZ and join us in contributing to a life without cancer!
Apply nowWe are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude.
Notice: We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles.
Share this job!
Deutsches Krebsforschungszentrum | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de